Literature DB >> 32014028

Correction to: Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients.

Kilian-Simon Baumann1,2, Veronika Flatten3,4, Uli Weber5, Stefan Lautenschläger3,6, Fabian Eberle3,6, Klemens Zink3,4,7, Rita Engenhart-Cabillic3,6.   

Abstract

Following publication of the original article [1], we have been notified that the below text parts of the Discussion chapter should be changed.

Entities:  

Year:  2020        PMID: 32014028      PMCID: PMC6996163          DOI: 10.1186/s13014-020-1475-x

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


Correction to: Radiat Oncol https://doi.org/10.1186/s13014-019-1375-0 Following publication of the original article [1], we have been notified that the below text parts of the Discussion chapter should be changed. Currently the text is as follows: Discussion The influence of the Bragg peak degradation due to lung tissue on treatment plans of lung cancer patients was investigated. For all cases the treatment-planning system overestimated the dose delivered to the CTV and in some cases underestimated the dose delivered to distal OARs. This effect increases with an increasing modulation power. The maximum underestimation of the mean dose Dmean is − 5% for the CTV and an extreme modulation power of 800 μm. The average underestimation is in the order − 2%. This extreme modulation power of 800 μm can occur in cases where a larger bronchial structure in the lung is positioned in the proton beam. However, for a more realistic modulation power of 450 μm, the underestimation of the mean dose Dmean is only about − 3% at maximum. The average underestimation is roughly − 1%. Altogether, the effects of the Bragg peak degradation are at maximum about 5% concerning the underestimation of the mean dose Dmean in the CTV when optimizing the treatment plan without considering the degradation due to the lung tissue. The above-mentioned text should be corrected as per below: Discussion The influence of the Bragg peak degradation due to lung tissue on treatment plans of lung cancer patients was investigated. For all cases the treatment-planning system overestimated the dose delivered to the CTV and in some cases underestimated the dose delivered to distal OARs. This effect increases with an increasing modulation power. The maximum overestimation of the mean dose Dmean is 5% for the CTV and an extreme modulation power of 800 μm. The average overestimation is in the order 2%. This extreme modulation power of 800 μm can occur in cases where a larger bronchial structure in the lung is positioned in the proton beam. However, for a more realistic modulation power of 450 μm, the overestimation of the mean dose Dmean is only about 3% at maximum. The average overestimation is roughly 1%. Altogether, the effects of the Bragg peak degradation are at maximum about 5% concerning the overestimation of the mean dose Dmean in the CTV when optimizing the treatment plan without considering the degradation due to the lung tissue.
  1 in total

1.  Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients.

Authors:  Kilian-Simon Baumann; Veronika Flatten; Uli Weber; Stefan Lautenschläger; Fabian Eberle; Klemens Zink; Rita Engenhart-Cabillic
Journal:  Radiat Oncol       Date:  2019-10-25       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.